In one paragraphArticle in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
52 authors.
René LattmannGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
Anika WuestefeldClinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.ORCID 0000-0003-1779-3388 Laura E M WisseDiagnostic Radiology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.ORCID 0000-0001-7504-3943 Trevor GlennPenn Image Computing and Science Laboratory (PICSL), Department of Radiology, University of Pennsylvania, Philadelphia, USA.ORCID 0000-0002-8626-7587 Barbara Marcos MorgadoDepartment of Psychiatry and Psychotherapy, University Medical Center Goettingen, Goettingen, Germany.ORCID 0000-0001-8174-9301 Hermann EsselmannDepartment of Psychiatry and Psychotherapy, University Medical Center Goettingen, Goettingen, Germany.ORCID 0000-0001-5484-9710 Alfredo RamirezGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Björn H SchottDepartment of Psychiatry and Psychotherapy, University Medical Center Goettingen, Goettingen, Germany.ORCID 0000-0002-8237-4481 Matthias C SchmidGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Stefan HetzerBerlin Center for Advanced Neuroimaging, Charité - Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0002-1773-1518 Peter DechentMR-Research in Neurosciences, Department of Cognitive Neurology, Georg-August-University Goettingen, Goettingen, Germany.ORCID 0009-0006-4005-3352 Klaus SchefflerDepartment for Biomedical Magnetic Resonance, University of Tübingen, Tübingen, Germany.ORCID 0000-0001-6316-8773 Eike SpruthGerman Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
Maria GemenetziGerman Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
Claudia BartelsDepartment of Psychiatry and Psychotherapy, University Medical Center Goettingen, Goettingen, Germany.ORCID 0000-0003-3023-9971 Daniel JanowitzInstitute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.
Boris-Stephan RauchmannDepartment of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany.ORCID 0000-0003-4547-6240 Sebastian SodenkampGerman Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
Oliver PetersGerman Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
Jens WiltfangDepartment of Psychiatry and Psychotherapy, University Medical Center Goettingen, Goettingen, Germany.ORCID 0000-0003-1492-5330 Katharina BuergerGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Emrah DüzelGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
DELCODE study group
Funding
A harmonized medial temporal lobe subregion segmentation protocol: an essential element for dementia researchR01AG070592 · NIA · WAYNE STATE UNIVERSITY · PI Ana Marie Daugherty, Rosanna Kathleen Olsen · 2022 to 2026
$3.5MNIA NIH HHS R01 AG070592
6 · The paper itselfAbstract
introductionStructural MRI often lacks diagnostic, prognostic, and monitoring value in Alzheimer's disease (AD), particularly in early disease stages. To improve its utility, we aimed to identify optimal MRI readouts for different use cases.
methodsWe included 363 older adults; healthy controls (HC) who were negative or positive for amyloidbeta (Aβ) and Aβ-positive patients with subjective cognitive decline (SCD), mild cognitive impairment, or dementia of the Alzheimer type. MRI and neuropsychological assessments were administered annually for up to three years.
resultsAccelerated atrophy of distinct MTL subregions was evident already during preclinical AD. Symptomatic disease stages most notably differed in their hippocampal and parietal atrophy signatures. Associations of atrophy markers and cognitive inventories varied by intended use and disease stage. DISCUSSION: With the appropriate readout, MRI can detect abnormal atrophy already during preclinical AD. To optimize performance, MRI readouts should be tailored to the targeted disease stage and intended use.
Identifiers
PMID40162264
PMCPMC11952614
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390